What is NuSirt Sciences?
NuSirt Sciences is a biotechnology firm dedicated to creating technologies that evaluate the impact of natural compounds and pharmaceuticals on chronic conditions associated with overnutrition and aging. Their core research targets cardiometabolic diseases, including metabolic-associated fatty liver disease, obesity, type 2 diabetes, and hypertension. The company has validated its therapeutic approaches through preclinical studies and clinical trials. NuSirt Sciences offers TRIPLN, a combination therapy, and LEUSIX, a dietary supplement designed to support cardiometabolic health and weight management, catering to individuals with these chronic conditions and healthcare professionals seeking advanced treatment options.
How much funding has NuSirt Sciences raised?
NuSirt Sciences has raised a total of $20.6M across 4 funding rounds:
Series B
$9.1M
Series A
$3.5M
Series C
$6M
Private Equity
$2M
Series B (2014): $9.1M, investors not publicly disclosed
Series A (2014): $3.5M led by William Guttman, Tennessee Community Ventures Fund, and Mountain Group Capital
Series C (2015): $6M supported by Hatteras Venture Partners, TriStar Technology Ventures, and Mountain Group Partners
Private Equity (2016): $2M, investors not publicly disclosed
Key Investors in NuSirt Sciences
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors. They partner with visionary founders to invest in innovative healthcare solutions that deliver therapeutic and diagnostic benefits while disrupting the status quo.
TriStar Technology Ventures
TriStar Technology Ventures is a company that operates in the Custom Software & IT Services industry. It employs 20to49 people and has 10Mto25M of revenue. The company is headquartered in Louisville, Kentucky.
Mountain Group Partners
Mountain Group Partners is a Nashville-based venture capital firm that specializes in investing in early-stage companies within the Life Sciences, AgTech, and Technology sectors. The firm focuses on unique and often underserved areas within these industries, taking an active approach to shape companies from their inception.
What's next for NuSirt Sciences?
With the recent major strategic investment, NuSirt Sciences is poised to accelerate its development pipeline, particularly for its TRIPLN combination therapy and the expansion of its LEUSIX dietary supplement. The company's focus on chronic diseases linked to aging and overnutrition places it in a rapidly growing market segment. Future endeavors will likely involve further clinical validation, potential commercialization partnerships, and expanding its therapeutic offerings to address a broader spectrum of age-related and metabolic disorders. The substantial capital infusion signals a critical growth phase, aiming to translate its scientific advancements into tangible health solutions.
See full NuSirt Sciences company page
